Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study
Permanent link
https://hdl.handle.net/10037/25032Date
2015-11-10Type
Journal articleTidsskriftartikkel
Peer reviewed
Author
Bešević, Jelena; Gunter, Marc J; Fortner, Renée T.; Tsilidis, Konstantinos K; Weiderpass, Elisabete; Onland-Moret, N. Charlotte; Dossus, Laure; Tjønneland, Anne; Hansen, Louise; Overvad, Kim; Mesrine, Sylvie; Baglietto, Laura; Clavel-Chapelon, Françoise; Kaaks, Rudolf; Aleksandrova, Krasimira; Boeing, Heiner; Trichopoulou, Antonia; Lagiou, Pagona; Bamia, Christina; Masala, Giovanna; Agnoli, Claudia; Tumino, Rosario; Ricceri, Fulvio; Panico, Salvatore; Bueno-de-Mesquita, H. Bas; Peeters, Petra H.; Jareid, Mie; Quirós, J. Ramón; Duell, Eric J; Sánchez, María-José; Larrañaga, Nerea; Chirlaque, Maria-Dolores; Barricarte, Aurelio; Dias, Joana A.; Sonestedt, Emily; Idahl, Annika; Lundin, Eva; Wareham, Nicholas J.; Khaw, Kay-Tee; Travis, Ruth C.; Rinaldi, Sabina; Romieu, Isabelle; Riboli, Elio; Merritt, Melissa A.Abstract
Methods: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.
Results: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR ¼ 0.80, 95% CI ¼ 0.62–1.03) and a significant survival benefit in long-term MHT users (X5 years use vs never use, HR ¼ 0.70, 95% CI ¼ 0.50–0.99, Ptrend ¼ 0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.